Skip to Main Content
Try STAT+ TODAY
Trending:
First Opinion
Coronavirus
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Lipocine fatty liver drug study results don’t hold up to scrutiny

  • Adam Feuerstein

By Adam Feuerstein Jan. 17, 2019

Reprints

Red flags aplenty are sprouting from the clinical trial results disclosed by Lipocine (LPCN) on Thursday.

Lipocine’s stock price rose by nearly half after the small biotech issued a press release touting “meaningful” reductions in liver fat demonstrated by its experimental pill in a clinical trial. The data don’t hold up to scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

New data from several states show racial disparities in…
New data from several states show racial disparities in monkeypox infections
The campaign to rename monkeypox gets complicated
The campaign to rename monkeypox gets complicated
Experts debate: Are we playing with fire when we…
Experts debate: Are we playing with fire when we edit human genes?
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: Two children died after getting Novartis gene therapy;…
Pharmalittle: Two children died after getting Novartis gene therapy; monkeypox vaccine maker warns about splitting doses
Wyden wants details on Amgen’s U.S. taxes as part…
Wyden wants details on Amgen’s U.S. taxes as part of expanding probe into pharma practices

Recommended Stories